Flaviene Felix Torres

Flaviene Felix Torres

Auto-generated profile, based on publicly available information

Flaviene Felix Torres

Universidade Federal de Mato Grosso do Sul, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Cadernos de Saude Publica
Verified
Journal Article
Open access
VBVictoria Simões Bernardo
Victoria Simões Bernardo
FTFlaviene Felix Torres
Flaviene Felix Torres
DSDanilo Grünig Humberto da Silva
Danilo Grünig Humberto da Silva

22 November 2020 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
FTFlaviene F. Torres
Flaviene F. Torres
VBVictoria Simões Bernardo
Victoria Simões Bernardo
DSDanilo Grünig Humberto da Silva
Danilo Grünig Humberto da Silva
JOJéssika V. Okumura
Jéssika V. Okumura
CBClaudia R. Bonini-Domingos
Claudia R. Bonini-Domingos
Studies have shown that the loss of the FOXO3 transcriptional function is involved in the pathophysiology of some chronic erythroid disorders, including beta-thalassemia (β-thal). Therefore, the single nucleotide polymorphism (SNP) rs3800231 (35-2764A > G) could contribute to alterations in its transcriptional activity, acting as a modifier of β-thal phenotypic manifestations. In order to better understand the genotypic and/or allelic distributions among β-thal patients, we evaluated 83 β-thal heterozygous and 20 homozygous, compared to 117 individuals without hemoglobinopathies (control group). Additionally, we verified any influence of the FOXO3 polymorphism on clinical manifestations among β-thal homozygotes. We obtained higher frequencies of the wild-type homozygous (AA) and the wild-type allele (A) in the β-thal group (p < 0.0001 and p = 0.00014, respectively). The most common clinical manifestations found among β-thal homozygotes were iron overload (90%), splenomegaly (65%) and bone complications (35%), e.g., osteopenia/osteoporosis. We observed that close to 80% of the patients presenting such manifestations had the genotype AA. However, we did not find any significant involvement of the FOXO3 polymorphism in clinical manifestation occurrences. Thus, we concluded that the SNP rs3800231 did not play a significant role as a modifier of the clinical manifestations observed in the β-thal homozygotes studied.